Illumina has named Melina Cimler to be vice president of quality and regulatory affairs. She will lead the company's quality and regulatory organizations to support its development, manufacturing, and distribution activities. Cimler formerly worked in similar positions at Beckman Coulter, Abbott Molecular, and Gen-Probe. Prior to joining Illumina, Cimler was president of PandiaDx Consulting. She holds a PhD in pharmacology from the University of Washington.
As an incentive to join the company, Illumina has granted Cimler an option to purchase 120,000 shares of its common stock. The option's terms are an exercise price equal to the closing fair market value of Illumina's common stock on the grant date of July 12, 2010; a 10-year term, and vesting over four years with 25 percent of the option vesting one year from the grant date and 1/48th of the option vesting monthly thereafter.